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Abstract
Aim To report clinical follow-up at 6 months after implanta-
tion of the ultra-thin strut cobalt chromium SolarFlex stent in a
real-world setting.
Methods and results Patients (n=240) with single or multiple
vessel coronary artery disease undergoing percutaneous coro-
nary intervention (PCI) at four sites in Europe were enrolled in
the SOLSTICE (SolarFlex Stent in Routine Clinical Practice)
registry. Follow-up at 6 months was 100 %. Diabetes was
present in 29 % of the patients, 30 % presented with acute
myocardial infarction and 17 % had unstable angina. Of the
patients, 27 % had previously undergone PCI or coronary
artery bypass surgery. Lesion complexity was high (50 %
B2+C type lesions). Device success was achieved in 99.7 %
of cases and the major adverse cardiac event (MACE) rate was
5.8 % at 6 months of fol low-up. Target les ion
revascularisation (TLR) was 5.0 % at 6 months.
Conclusions The SOLSTICE registry showed that in a com-
plex real-world setting the SolarFlex bare metal stent, with
ultra-thin struts and customised scaffolding, provided low
clinical MACE and TLR rates. These results provide support
for the use of the latest generation bare metal stent in contem-
porary European practice.
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Introduction
Current clinical trials have shown that bare metal stents
(BMS) are generally associated with restenosis rates of be-
tween 10 and 15 %. [1–3]. Drug-eluting stents (DES) have
been widely adopted as the device of choice for the treatment
of coronary artery disease (CAD) and have proved to be more
efficacious than BMS, with clinical restenosis rates dropping
to below 10 % [4]. However, many DES systems are limited
in terms of flexibility and deliverability, increased costs rela-
tive to BMS, and the continued risk of late and very late stent
thrombosis [5–7].
While DES are inherently less prone to restenosis than
BMS, ongoing developments in understanding the interplay
between stent design and clinical outcomes provide scope for
narrowing the efficacy gap between BMS andDES, especially
in larger vessels where the restenosis rates of DES and BMS
already begin to converge [8]. Clinical studies such as the
ISAR STEREO and ISAR STEREO II trials have demonstrat-
ed the significant advantage of thinner stent struts in reducing
restenosis rates [1, 2], and first-generation cobalt chromium
(Co-Cr) stents allowed stent designs with much thinner struts
compared with the older stainless steel stents. Early generation
Co-Cr stents had a strut thicknesses of 81–91 μm.While these
dimensions likely conferred some efficacy benefits, a number
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of studies [1, 2, 6, 9, 10] have shown that optimal strut
dimensions should remain below 75 μm in order to ensure
rapid endothelialisation of the implant, which in turn is be-
lieved to decrease neointimal proliferation.
The primary aim of this post-market, non-randomised,
multi-centre, prospective SOLSTICE (SolarFlex Stent in
Routine Clinical Practice) registry was thus to assess the
safety and efficacy of an ultra-thin strut L605 Co-Cr bare
metal stent, the SolarFlex, in a real-world setting.
Methods
Data collection and monitoring
The study protocol was approved by the Ethics Committee at
each site and each patient provided written informed consent.
Patient demographics, presenting conditions, risk factors and
procedural outcomes were recorded on Case Report Forms
(CRF) at baseline and all major adverse cardiac events
(MACE), were recorded in-hospital and at follow-up. CRFs
were monitored and reviewed by an independent Clinical
Research Associate (CRA) and all reported MACE were
reviewed by an independent arbitrator.
Patient population
Patients older than 18 years of age, with lesion lengths of
25 mm or less, where a maximum of three de novo or (non-
stented) restenotic lesions could be planned to each be fully
covered by a single stent, were included in the registry. The
following exclusion conditions applied: refractory lesions that
could not be pre-dilated at 20 atm; cardiogenic shock; known
contraindications or allergy to aspirin, antiplatelet treatment or
the stent material; did not qualify for treatment with the
necessary concomitant medication; pregnancy; left main dis-
ease; history of previous in-stent restenosis; implantation of a
drug-eluting stent in the study artery during the same
procedure.
Initially 243 patients provided consent but according to the
completed CRFs three patients did not meet all the inclusion
and exclusion criteria and thus data were collected for the 240
patients who did fully met the criteria.
Balloon angioplasty and stent implantation were performed
according to standard clinical practice in the participating
centres and the recommendations of the SolarFlex
Instructions for Use. Criteria for whether to implant a BMS
or a DESwere based on the current practices of each particular
site. It was recommended that an appropriate dual antiplatelet
regimen should be strictly adhered to for at least 30 days after
the intervention.
The SolarFlex stent system
The SolarFlex stent system consists of a cylindrical,
electropolished, Co-Cr corrugated ring balloon-expandable
stent mounted on a rapid-exchange coronary stent delivery
catheter. The stent has an ultra-thin strut thickness down to
65 μm. Five different stent cellular configurations are used to
span the five diameters of the full range, as illustrated in Fig. 1
(stents range from 12 struts around the circumference for
2.5 mm stents to 20 struts around the circumference for
4 mm stents). The stent system was available in 2.5, 2.75,
3.0, 3.5 and 4.0 mm diameters and 11, 14, 17, 20, 24 and
28 mm lengths. The stent has a low crimped profile down to
0.84 for 2.5 mm stents.
Definitions
Clinically driven target lesion revascularisation (cTLR) was
defined as any repeat percutaneous intervention of the study
stent or bypass surgery of the target vessel due to symptoms or
functional evidence of ischaemia in the presence of a percent
diameter stenosis ≥50 %, or percent diameter stenosis of
≥70 % even in the absence of ischaemic signs or symptoms.
MACE was defined as the composite of cardiac death,
myocardial infarction (MI) attributable to the target vessel,
and cTLR. Any deaths due to proximate cardiac cause,
unwitnessed death and death of unknown cause, and all
procedure-related deaths, including those related to concomi-
tant treatment, were classified as cardiac death. MI was de-
fined as the presence of elevated troponin T or troponin I
greater than three times the upper limit of normal. Stent
thrombosis (definite or probable) was defined using the
Academic Research Consortium definition [11].
Device success was defined as the ability to reach and cross
the target lesion, deploy the stent and withdraw the stent
delivery catheter, with the attainment of a post-stent diameter
residual stenosis ≤30%with ≥ TIMI 2 flow with the treatment
device alone; standard pre-dilation and post-dilation catheters
could be used. Procedural success was defined as device
success with freedom from in-hospital MACE.
Follow-up
All patients were followed up for 6 months after treatment
either by clinical examination by the investigator or a tele-
phone interview. Interviews were used to evaluate the occur-
rence of cTLR and MACE within the follow-up period.
Statistical analysis
Continuous variables were presented as mean ± standard
deviation and categorical variables were presented as counts
and percentages.
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Results
Patient demographics
Four European centres enrolled 240 patients who met all the
inclusion and exclusion criteria in the period from April 2011
to January 2012. The average age of the patients was 66 years,
with the majority being male (74 %). Over one-quarter of
patients (29 %) were diabetic. A notably large number
(30 %) of patients presented with acute MI (AMI). The full
patient demographics and baseline clinical characteristics are
given in Table 1.
Angiographic characteristics
The baseline angiographic characteristics are shown in
Table 1. The vessels treated were primarily the left anterior
descending artery (36 %) and right coronary artery (37 %).
Significantly, over 50 % of lesions were categorised as com-
plex (B2 + C type) according to the modified American
College of Cardiology (ACC) and the American Heart
Association (AHA) classification [12].
Procedural characteristics
In total 292 lesions were treated with 293 stents, representing
1.2 stents per patient. Pre-dilatation was performed in 60 % of
the lesions while post-dilatation was carried out in 21 % of the
lesions. The reason for stenting was primarily elective (90 %).
The average stent diameter used was 3.15mmwith an average
length of 17.47 mm. All devices reached the target lesion and
a 99.7 % device success rate was achieved. The procedural
success rate was 97.5 %. Procedural data are recorded in
Table 2.
Clinical follow-up
Follow-up at 6 months was 100 % The cumulative rate of
cTLR at 6 months was 5.0 %. A single case of cardiac death
occurred before 30 days which, by definition, was attributed to
a probable stent thrombosis. This patient was a 77-year-old
male smoker with a previous history of MI who presented
with unstable angina and who died of unknown causes 1 week
after PCI. A second patient died of non-cardiac related causes
(thus not considered a MACE). Total MACE at 6 months was
5.8 %.
Discussion
While DES continue to be more efficacious than BMS, pa-
tients treated with BMS for such reasons as limited financial
resources or contraindication to dual antiplatelet therapy still
have excellent outcomes in modern clinical practice. This is
demonstrated through ongoing BMS registries and meta-
analyses and thus continues to warrant further study of BMS
[13].
A review of all multi-centre registries or clinical trials of
single Co-Cr stent types with more than 100 patients and 6–
9 month follow-up was carried out to analyse the results from
the SOLSTICE study in the context of other Co-Cr bare metal
stents. (Note that studies restricted to patients presenting with
STEMI were also excluded from this review). A comparison
of the key results of these studies is shown in Table 3.
Randomised trials have demonstrated that BMS with thin
struts result in lower restenosis rates than thick-strut stents [1,
2]. The current understanding of stent design has also dem-
onstrated the advantages of greater scaffolding support [14].
This is supported by computational fluid dynamics which has
shown that increasing the number of struts around the circum-
ference results in a smaller intrastrut area exposed to low wall
shear stress [15]. Increased scaffolding comes at the expense
of increased metal-to-artery contact, which is thought to ex-
acerbate any foreign body effects of the implant, and a denser
crimped configuration. Applying these principles to the
SolarFlex stent, a customised scaffold structure was created
where each stent diameter has its own cell design to provide
uniform support over all artery sizes. The MACE data, while
often difficult to compare between studies because of varying
definitions, reveal the SolarFlex stent to have a very low
MACE rate (5.8 %) compared with the other studies detailed
in Table 3, a fact which may be attributable to the application
of these stent design principles. In addition, the cumulative
Fig. 1 Schematic illustration
showing the uniform distance
between stent struts over all five
stent sizes
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TLR results for the study (5.0 %) compare favourably with
other studies in the selection (bar that of the study of the
Vision stent carried out by Xu et al. [16] which appears to
have an atypical cTLR rate of 1.4 % when compared with the
other studies of this same stent carried out by Kereiakes et al.
[17] and Brambilla et al. [18] which have TLR rates of 4.3 and
5.8 % respectively. It should be noted that the mean stent
diameter in our study was above 3.0 mm and the mean stent
length was below 20mm, which predict relatively low rates of
restenosis. The sizes of the SolarFlex in the study do, howev-
er, fall within the same range as the other studies.
While substantially more data have been collected on L605
Co-Cr stents that other Co-Cr alloys, choosing L605 as BMS
material may provide clinical advantages. The average TLR rate
of the L605 alloy stents is 4.5 % compared with that of 8.5 % for
the MP35N alloy, with average MACE rates being 8.3 and
10.4 % respectively. The single study using the Phynox alloy
demonstrated a TLR rate of 6 % and a MACE rate of 13 %.
While DES tend to suffer from limited deliverability and
flexibility (due to the presence of coatings, less firm crimping
procedures, and the use of earlier generation BMS platforms)
Table 1 Baseline clinical and angiographic characteristics
Number of patients 240
Age (years) 66±12.6
Male (%) 178 (74 %)
Baseline angina status
Asymptomatic 7 (2.9 %)
Silent ischaemia 12 (5.0 %)
Stable 108 (45.0 %)
Unstable 40 (16.7 %)
AMI 73 (30.4 %)
History of
MI 67 (27.9 %)
CABG 16 (6.7 %)
PCI 71 (29.6 %)
Risk factors
Diabetes mellitus type 1 38 (16 %)
Diabetes mellitus type 2 31 (13 %)
Hypertension 138 (58 %)
Cholesterol 142 (59 %) [n=239]a
Family history 114 (48 %) [n=237]a
Smoking 186 (22 %) [n=238]a
Number of lesions 292
Target lesion classification
A 50 (17.1 %)
B1 92 (31.5 %)
B2 110 (37.7 %)
C 37 (12.7 %)
Unknown 3 (1.0 %)
Vessels treated
Heft anterior descending 106 (36.3 %)
Right coronary artery 108 (37.0 %)
Circumflex 74 (25.3 %)
Saphenous valve graft 3 (1.0 %)
Ramus 1 (0.3 %)
Angulation
<45° 236 (80.8 %)
≥45° 47 (16.1 %)
≥90° 7 (2.4 %)
Unknown 2 (0.7 %)
Tortuosity
Low 186 (63.7 %)
Moderate 86 (29.5 %)
High 18 (6.2 %
Unknown 2 (0.7 %)
Complexities
Bifurcation 35 (12.0 %)
Ostial 15 (5.1 %)
Thrombus 32 (11.0 %)
Calcification 77 (26.4 %)
Diffuse disease 32 (11.0 %)
Involves side branch 12 (4.1 %)
aWhere data were not available for all patients the number of patients
with data is indicated (n)
Table 2 Clinical outcomes




Predilation 176 (60.1 %)
Direct stenting 117 (39.9 %)
Post-dilation 60 (20.5 %)
Reason for stenting
Elective 265 (90.4 %)
Dissection 23 (7.8 %)
Other 5 (1.7 %)
Delivery success (stents reaching lesion) 293 (100 %)
Device success (per stent) 292 (99.7 %)
Procedural success (per patient) 234 (97.5 %)
Follow-up 240 (100 %)
In-hospital events
Total MACE 5 (2.1 %)
Cardiac death 0
Myocardial infarction 1 (0.4 %)
Target lesion revascularisation 4 (1.7 %)
Stent thrombosis (definite) 3 (1.3 %)
6-month outcome (cumulative)
Total MACE 14 (5.8 %)
Cardiac death 1 (0.4 %)
Myocardial infarction 3 (1.2 %)
Target lesion revascularisation 12 (5.0 %)
Stent thrombosis (probable) 1 (0.4 %)
Stent thrombosis (definite) 4 (1.7 %)
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Co-Cr BMS have a high delivery success rate as shown for all
the studies listed in Table 3. Data relating to the Abbott
Vascular (formerly Guidant) Multilink family of stents pro-
vides an interesting case study to demonstrate the evolution of
deliverability for Co-Cr stents to parallel improved clinical
data for its Co-Cr Multilink Vision stent. A decade ago,
Kereiakes et al. [17] showed, for this family of stents, that late
lumen loss is related to strut thickness, and that the relative
biocompatibility of Co-Cr is also supported by this data.
Interestingly, as Ormiston et al. show [19], a steady reduction
in crossing profile has been linked to improved deliverability,
with the early generation Multilink stent having a crossing
profile of 1.53 mm showing worse trackability than the
Multilink Duet, which has a crossing profile in the order of
1.17 mm, despite both systems having similar flexibility. The
continued pursuit of improved deliverability has thus driven
profiles for commercial stents down even further to the order
of 1 mm [20], with the SolarFlex 3.5 mm delivery system
having a crimped profile of 0.98 mm. A relatively high direct
stenting rate in the complex real-world setting of this
SOLSTICE study of 39.9 %, together with a delivery success
rate of 100 %, supports this evidence for efficient deliverabil-
ity of a BMS ultra-thin strut Co-Cr system. The technological
improvements related to BMS deliverability have kept pace
with improvements in clinical outcome.
Four cases of definite stent thrombosis were recorded dur-
ing the SOLSTICE study and an interrogation of these cases
reveals that all four of the patients presented with AMI. While
the mechanism of stent thrombosis is not limited to a single
factor (various factors related to the procedure, lesion and
patient are relevant), it is known that patients presenting with
AMI have an increased risk of stent thrombosis [21].
Study limitations
A lack of angiographic follow-up can represent a study limi-
tation; however, clinical endpoints, as used in the SOLSTICE
study, are possibly of more relevance for assessment of patient
outcomes. Although lack of randomisation is a limitation, the
study sought to examine real-world clinical safety and effec-
tiveness in a milieu of provenDES superiority. Approximately
2840 PCIs were performed in the four centres over the study
enrolment period, while only 240 patients were enrolled in the
registry; selection bias is therefore possible.
Conclusions
Positive developments in bare metal stent material and design
understanding continue to be seen through the improving clinical
data being gathered in real-world registries. Judicious use of
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outcomes, as is suggested in this study by the low MACE and
TLR rates of an ultra-thin strut L605 cobalt-chromium baremetal
stent with a customised cell design providing uniform support
over all artery sizes in the stent range.
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